# Addpharma Inc.

Organization · id `cardio:org-addpharma-inc` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Addpharma+Inc.>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 10 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Addpharma Inc.
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan (`cardio:ct-nct03872232`)
- Sponsors: Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine (`cardio:ct-nct04158076`)
- Sponsors: Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension (`cardio:ct-nct04218552`)
- Sponsors: A Study to Evaluate the Efficacy and Safety of AD-209 (`cardio:ct-nct05631990`)
- Sponsors: A Study to Evaluate the Efficacy and Safety of AD-223 (`cardio:ct-nct06052748`)
- Sponsors: A Study to Evaluate the Efficacy and Safety of AD-224 (`cardio:ct-nct06291207`)
- Sponsors: Phase III Study to Evaluate the Efficacy and Safety of AD-209 (`cardio:ct-nct06348576`)
- Sponsors: A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B (`cardio:ct-nct06441630`)
- Sponsors: Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 (`cardio:ct-nct06448962`)
- Sponsors: A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy (`cardio:ct-nct07816198`)

## Provenance

Content hash: bc97713feba7166bf9109a3ddda15d1ac61a6815332e15e44bd18d965e4ece39
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
